Recent

% | $
Quotes you view appear here for quick access.

IntelliPharmaCeutics International Inc. Message Board

sam_0534 210 posts  |  Last Activity: 16 hours ago Member since: Feb 8, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • It clutters the site and feeds the posters want for attention...JUST put them on IGNORE please...you are wasting your time and others ...thank you...

  • now figuring out WHY??? 321,000 shares got out today.. so many speculators around...and dont look at the prospects, etc of this company...distorts the chart and make big swings...

    Sentiment: Strong Buy

  • BX has been consolidating nicely and stocastics coming off overbought and the 20 dma is excellent support underneath...so looking good to me..

    Sentiment: Strong Buy

  • Reply to

    PF - Pinnacle Foods

    by rkahn29720 May 27, 2015 9:53 AM
    sam_0534 sam_0534 May 27, 2015 1:13 PM Flag

    BX only owns 204,500 shares of PF..only 5 million $....

  • sam_0534 sam_0534 May 27, 2015 12:48 PM Flag

    this was no pump and dump..this was valid positive news..just the traders got screwed and trying to get out..but the patient investor will win this one..always been a volatile stock..

    Sentiment: Strong Buy

  • but constructive that it did...now like to see the buying come back.. will see..

    Sentiment: Strong Buy

  • anything is possible...patient long term investor here....Retrophin Sells FDA Voucher to Sanofi for $245 Million
    Obtained priority-review voucher as part of Cholbam acquisition
    By CHELSEY DULANEY
    Updated May 27, 2015 9:18 a.m. ET
    Retrophin Inc. on Wednesday said it agreed to sell a special voucher meant to speed drug approval to French drug maker Sanofi SA for $245 million in cash.

    Sentiment: Strong Buy

  • big opening gap being filled.. just a tug of war with the short term traders and longer term patient investors...dont think this gap needs to be filled with the positive news and prospects...next couple of days will see how the trading settles down....stocastics still giving a BUY signal....chart looking good...

    Sentiment: Strong Buy

  • IntelliPharmaCeutics Intl Inc logoBrean Capital restated their buy rating on shares of IntelliPharmaCeutics Intl (NASDAQ:IPCI) in a report released on Saturday. Brean Capital currently has a $8.00 price objective on the stock.

    IPCI has been the subject of a number of other recent research reports. Analysts at TheStreet downgraded shares of IntelliPharmaCeutics Intl from a hold rating to a sell rating in a research note on Monday, May 18th. Analysts at Zacks downgraded shares of IntelliPharmaCeutics Intl from a strong-buy rating to a hold rating in a research note on Wednesday, May 13th. Finally, analysts at Nomura downgraded shares of IntelliPharmaCeutics Intl to a neutral rating in a research note on Tuesday, February 24th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. IntelliPharmaCeutics Intl presently has an average rating of Hold and an average price target of $7.50.

    Sentiment: Strong Buy

  • Intellipharmaceutics Announces Agreement to Acquire Real Property that Houses its Manufacturing, R&D and Office Facilities in Toronto, Ontario and Status of 5mg Strength of its Generic Focalin XR(R)
    Intellipharmaceutics International Inc.
    13 hours ago
    GlobeNewswire
    
    Related Quotes
    I.TO
    4.35
    +7.41%
    IPCI
    3.45
    +11.29%
    IntelliPharmaCeutics Internati … Watchlist
    4.35+0.30(7.41%)
    Toronto9:15AM EST

    IntelliPharmaCeutics International (IPCI) in Focus: Stock Jumps 5.4% - Tale of the Tape Zacks 1 hr 7 mins ago
    IntelliPharmaCeutics Int'l. (IPCI) Stock Spikes on Positive Non-Abusive Oxycontin Development TheStreet q 4 days ago
    More
    TORONTO, May 25, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has agreed to purchase the land and building from which it conducts its operations at 30 Worcester Road, Toronto, Ontario (the "operating property") as well as the land and building of the adjoining property at 22 Worcester Road (the "adjoining property") for a combined purchase price of Cdn. $4,700,000. The operating property has been occupied by the Company since 2004 pursuant to a lease, and is approximately 25,000 sq. ft. The adjoining property includes a building of approximately 40,000 sq. ft. that is not currently occupied by the Company. The adjoining property is expected to provide the Company with space that will permit expansion of the Company's operations. There can be no assurance that the purchase transaction will be completed.

    The Company's operating property has been its main site for over 10 years and comprises its management, R&D, manufacturing, quality control and analytical testing components. The United States Food and Drug Administration ("FDA") and Health Canada had previously granted "acceptable" classification to those aspects of the operating facility that permit the Company to be in a position to receive final approvals for certain drug applications and to permit manufacturing, testing, release and storage of drug products intended for commercial sales in the United States and Canada after any such approvals. No assurance can be given as to whether or when the FDA or Health Canada will approve any Intellipharmaceutics application for its product candidates, that its facility will continue to satisfy the requirements of the FDA or Health Canada, or that any of its product candidates will be successfully commercialized.

    The purchase transaction is subject to various closing conditions, including the Company obtaining financing that is satisfactory to the Company, and the property owner obtaining a municipal severance approval necessary for the transfer of the properties. Prior to entering into the agreement to acquire the properties, in order to ensure continuity of use of its operating property in the event the acquisition was not consummated, the Company also recently exercised its right to renew its lease of the operating property for a term of five years to November 2020, beyond the expiry of the current term ending November 30, 2015.

    "I am very pleased we have taken these steps to secure the continued use of our existing operating facilities. In addition, if the acquisition transaction proceeds, the acquisition of the adjoining property will accommodate our anticipated growth requirements given the numerous product candidates of the Company pending regulatory approval," stated Dr. Isa Odidi, the Company's Chair and CEO.

    Separately, the Company advised that a final FDA approval has not yet been issued to the Company for the 5 mg strength of its generic dexmethylphenidate generic of Focalin XR(R). Although the Company has not received any indication from the FDA of a deficiency in its application for approval of the 5 mg strength, the Company has no further information as to when or if such final approval will be granted by the FDA.

    Sentiment: Strong Buy

  • or 6.81 %

    Sentiment: Strong Buy

  • sam_0534 sam_0534 May 25, 2015 10:09 AM Flag

    nice if people post articles about BX.....

    Sentiment: Strong Buy

  • Aschoff wrote, “We estimate that the freedom to forego Phase 3 testing will shave off at least $20 million from the cost of development, as well as about 18-24 months of time. The NDA process should now only cost Intellipharmaceutics about $1-1.5 million. We believe that the FDA was satisfied with the bioequivalence data in the IND and thus what remains to be completed prior to NDA submission primarily involves six-month stability testing comparing bioequivalence before and after the six-month period.”

    The analyst rates IntelliPharmaCeutics shares a Buy, with an $8 price target, which implies an upside of 172% from current levels.

    Sentiment: Strong Buy

  • Reply to

    UPGRADE

    by jack_mlyn May 22, 2015 9:14 AM
    sam_0534 sam_0534 May 22, 2015 9:41 AM Flag

    the reputation of the firm is more important....

    Sentiment: Strong Buy

  • Reply to

    Stocastics giving a low risk buy signal..

    by sam_0534 May 21, 2015 8:26 PM
    sam_0534 sam_0534 May 21, 2015 8:29 PM Flag

    still need a good close above the 3 level...

  • Reply to

    Stocastics giving a low risk buy signal..

    by sam_0534 May 21, 2015 8:26 PM
    sam_0534 sam_0534 May 21, 2015 8:27 PM Flag

    check stockcharts...com

  • turning up from deep oversold.. being a news item stock hard to tell what will happen.. chart looks great..but traders and spec confuse the trends....http://stockcharts.com/h-sc/ui

    Sentiment: Strong Buy

  • NXP CEO Clemmer Talks Merger, Debt, and Why the Stock’s So Low
    Email
    Print

    smaller
    Larger
    By Tiernan Ray

    NXP Semiconductors CEO Rick Clemmer at Barron's offices, May 21st, 2015.
    NXP Semiconductors CEO Rick Clemmer at Barron’s offices, May 21st, 2015.
    Later this year, NXP Semiconductors (NXPI) will merge with Freescale Semiconductor (FSL) in an $11.8 billion deal announced back in February.

    Fresh from a J.P. Morgan tech conference in Boston, NXP CEO Rick Clemmer swung by Barron’s offices on Thursday for a brief chat.

    The merger will make the combined entity the world’s fourth biggest independent chip company — outside of memory chips — behind Intel (INTC), Qualcomm (QCOM), and Texas Instruments (TXN), where NXP is currently fourteenth and Freescale is 18th.

    Why’s our stock so low?

    Said Clemmer, “One thing we got questions from is why is out stock so low,” he said, reflecting on the chat in Boston. Despite being up 76% in the last twelve months, NXP fetches just ten times what one bull, Stacy Rasgon of Bernstein, last month argued is the combined value of the two companies’s potential earnings.

    Clemmer agrees with Rasgon, mentioning his coverage initiation a couple times in the chat.

    So, why’s it so cheap? “You’d have to ask them,” he says, meaning investors. But he’s willing to hazard a guess that investors don’t really understand one of the emerging growth areas: Internet of Things.

    NXP is going to have the most comprehensive offering for IoT, he says, repeating a claim he made during my meeting with him in Barcelona in February.

    “If you look at the total solution [for IoT], it’s the sensing part, the sensors themselves, which we think has become basically a commodity business, and so we see no reason to participate there.”

    “But then you also have to have the computing, the connectivity features, and the security.”

    “Well, we had the security and the connectivity parts, but we didn’t have all we needed on the microcontroller side, because we were in areas that were very narrow.”

    With Freescale, NXP will be the top vendor of general-purpose microcontrollers, he notes. Last year, NXP was the fastest-growing in the market, and Freescale was the second-fastest-growing.

    In sum, “IoT will be significant growth area” for NXP, he says.

    Security tech is going to be big

    Then, too, “We are a complex story because of the security aspect,” he says, meaning NXP’s chips for the “secure element” inside Apple’s iPhone, which holds your personal credentials, and also NXP’s work on e-passports.

    Clemmer repeated a claim he’s made frequently, namely that “In an IoT world, security will play a key role” because all these connected things will be even more prone to hacking and theft and such, and they increasingly carry personal data. “You need the ruggedized security of a hardened secure element,” he says, making a pitch for NXP’s offering.

    Deal approval progress

    Among other things that were top of mind, said Clemmer, was that Qualcomm (QCOM) had announced a week ago that they would get out of the business of making their own chips for “near-field communications,” the standard for so-called contactless payments (think Apple‘s (AAPL) Apple Pay) and would partner with NXP, a nice little win for Clemmer.

    But also there had been questions from investors at the JP Morgan event as to whether regulators might still block the merger.

    “We don’t have regulatory concerns,” said Clemmer. “We’re working selling the high-power RF business,” a power amplifier line that would have 80% to 90% of the market with the combined company, which has been one of the requirements of the combination. “We are in discussions with a few guys for that, and targeting June to complete that.”

    What else might they sell?

    Regarding what else the company might sell, I asked about “standard products,” a catalog business of many, many kinds of discrete chips, which can be more volatile than the other parts of NXP. Bernstein’s Rasgon, for one, wonders whether it could be a sale candidate.

    “If someone would pay fair value for it we would consider it,” said Clemmer of a sale of the unit. On the negative side, “It doesn’t run the same profit margin as HPMS [high-performance mixed-signal, today 75% of NXP's revenue]: it’s 20% operating margin or so, versus 27% or better for HPMS,” and also standard is “not as sticky,” meaning you have to keep winning deals for the chips quarter after quarter. “It has more volatility because you have to have RFQs on a monthly basis.”

    Still, it’s a business that churns out an amazing 70 billion units a year, and 40% of standard product sales comes from automotive, which will be the crown jewel of the combined company, with a number one share in semis for that market.

    So, what would a fair price be? Well, “it has better performance than ON [Semiconductor] (ONNN) or Fairchild [Semiconductor] (FCS),” he notes, implying the unit would have to at least fetch the kinds of multiples those companies get for similar business.

    Debt is a good thing

    We closed out the chat with discussion of the substantial debt pile the company will have after the merger, about 3 times debt to Ebitda, fairly high for a tech company.

    NXP will bring that down to just two times within five quarters of the Freescale deal closing, Clemmer said, repeating promises he made at the deal announcement.

    Some of that will happen by absorbing Freescale’s larger debt pile at rates considerably more favorable, with some Freescale debt tranches having rates as high as 10%, he notes. A “big chunk” will be refinanced.

    But debt is good, was Clemmer’s main point. “A lot of semiconductor companies have lazy balance sheets,” he says, with little to no debt. “If you can finance at a low cost in return for double-digit equity returns, that’s a good thing to do,” said Clemmer.

    Every company should have some debt, he argues, and generally should aim for zero or negative net cash. What if rates rise? Doesn’t change things. “Even if your cost were to go up to 5%, it still makes sense to do it [take on debt] if you’re going to get double digit equity returns.”

    I offered the example of Intel’s CFO, Stacy Smith, who argues for a “zero-cash” approach to the balance sheet. “That’s good,” he says, “But they’ve got very little debt.”

    “If you have a net cash balance of any kind, you’re not doing all you can do,” he says.

    NXP shares today are up $3.58, or 3.5%, at $106.40.

    Sentiment: Buy

  • short term traders playing today..not many long term investors...but the news was excellent...

    Sentiment: Buy

  • IntelliPharmaCeutics Intl Downgraded by TheStreet (IPCI)

    Posted on May 20, 2015 by Jamal Genner in Analyst Articles - US, Investing

    IntelliPharmaCeutics Intl Inc logoTheStreet lowered shares of IntelliPharmaCeutics Intl (NASDAQ:IPCI) from a hold rating to a sell rating in a report released on Monday.

    Sentiment: Strong Buy

IPCI
3.19-0.03(-0.93%)3:20 PMEDT